The basal insulin analogue LY@ , a PEGylated insulin lispro with prolonged duration of action , was previously shown to be associated with modest weight loss in Phase @ , randomized , open-label trials in type @ ( N = @ ) and type @ ( N = @ ) diabetes mellitus ( T@DM and T@DM ) , compared with modest weight gain with insulin glargine .